NASDAQ:AZN - Nasdaq - US0463531089 - ADR - Currency: USD
Taking everything into account, AZN scores 6 out of 10 in our fundamental rating. AZN was compared to 197 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are quite some concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AZN.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.31% | ||
ROE | 18.94% | ||
ROIC | 14.1% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 24.05% | ||
PM (TTM) | 14.14% | ||
GM | 82.36% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | 3.46 | ||
Altman-Z | 2.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.9 | ||
Quick Ratio | 0.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 16.13 | ||
Fwd PE | 13.46 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 24.08 | ||
EV/EBITDA | 12.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.34% |
70.96
+0.55 (+0.78%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 16.13 | ||
Fwd PE | 13.46 | ||
P/S | 4 | ||
P/FCF | 24.08 | ||
P/OCF | 16.81 | ||
P/B | 5.36 | ||
P/tB | N/A | ||
EV/EBITDA | 12.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.31% | ||
ROE | 18.94% | ||
ROCE | 17.15% | ||
ROIC | 14.1% | ||
ROICexc | 15.14% | ||
ROICexgc | 76.66% | ||
OM | 24.05% | ||
PM (TTM) | 14.14% | ||
GM | 82.36% | ||
FCFM | 16.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | 3.46 | ||
Debt/EBITDA | 1.47 | ||
Cap/Depr | 58.81% | ||
Cap/Sales | 7.18% | ||
Interest Coverage | 9.49 | ||
Cash Conversion | 65.63% | ||
Profit Quality | 117.58% | ||
Current Ratio | 0.9 | ||
Quick Ratio | 0.7 | ||
Altman-Z | 2.97 |